Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 5/20 | 0.50 |
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23459399 | 0.98 | POLB (0.58) | POLBHTR6LTA4HHRH3GHSR | |
| SCHEMBL1485223 | 0.95 | HTR6 (0.55) | POLBHTR6GHSRHTR2A | |
| SCHEMBL20109493 | 0.95 | HTR6 (0.55) | POLBHTR6GHSRHTR2A | |
| SCHEMBL31553321 | 0.81 | POLB (0.49) | POLBHTR6HRH3HTR2A | |
| SCHEMBL20828122 | 0.80 | POLB (0.60) | POLBHTR6LTA4HHRH3HTR2A | |
| SCHEMBL17979696 | 0.80 | POLB (0.60) | POLBHTR6LTA4HHRH3GHSR | |
| SCHEMBL17979768 | 0.80 | CHRNB4 (0.58) | POLBHTR6LTA4H | |
| SCHEMBL18019873 | 0.80 | CHRNB4 (0.58) | POLBHTR6LTA4H | |
| SCHEMBL18019869 | 0.80 | CHRNB4 (0.58) | POLBHTR6LTA4H | |
| SCHEMBL11479395 | 0.79 | POLB (0.58) | POLBHTR6LTA4HHRH3GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101903347-B | Piperidinyl and piperazinyl modulators of gamma-secretase | JANSSEN PHARMACEUTICA NV | 2013-03-27 | — | — | CN | disclosed |
| US-8252935-B2 | Piperidinyl and piperazinyl modulators of γ-secretase | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-28 | — | — | US | disclosed |
| EP-2212287-B1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-02-01 | — | — | EP | disclosed |
| CN-101903347-A | Piperidinyl and piperazinyl modulators of gamma-secretase | JANSSEN PHARMACEUTICA NV | 2010-12-01 | — | — | CN | disclosed |
| EP-2212287-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | Janssen Pharmaceutica, N.V. (BE) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009052126-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF γ-SECRETASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-04-23 | — | — | WO | disclosed |
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105275-A1 | PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE | BACE1, BACE2, PSEN1 | POLB 2544/4885HTR6 1121/4885LTA4H 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.